Events

Videos

Podcasts

Articles

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL

2019 ASH; Best Abstracts for CLL

CAR T-Cell Therapy for Relapsed/Refractory CLL

Sequencing Strategies for CLL

PI3 Kinase Inhibitors for Relapsed/Refractory CLL

Management of CLL Progression After Ibrutinib

Resistance to Therapy in CLL

Combinations for Relapsed or Refractory CLL

Fixed-Duration Therapy for Relapsed CLL

Health Maintenance in CLL

Distinguishing Features Among BTK Inhibitors

Combining Targeted Therapies in CLL

Ibrutinib + Venetoclax for CLL

Treatment for Younger Fit Patients With CLL

The Role of Venetoclax + Rituximab in CLL

Acalabrutinib, Second-Generation BTK Inhibitor for CLL

Long-Term Experience With BTK Inhibitors for CLL

Chemoimmunotherapy for CLL; Still a Role?

Mutation Status Throughout the CLL Clinical Course

Prognostic Factors in Patients With CLL

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 